770 related articles for article (PubMed ID: 32663198)
1. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
3. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
4. Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
Jachetti E; Sangaletti S; Chiodoni C; Ferrara R; Colombo MP
Cell Immunol; 2021 Apr; 362():104301. PubMed ID: 33588246
[TBL] [Abstract][Full Text] [Related]
5. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.
Lomphithak T; Akara-Amornthum P; Murakami K; Hashimoto M; Usubuchi H; Iwabuchi E; Unno M; Cai Z; Sasano H; Jitkaew S
Sci Rep; 2021 Jun; 11(1):11743. PubMed ID: 34083572
[TBL] [Abstract][Full Text] [Related]
6. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
[TBL] [Abstract][Full Text] [Related]
7. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
8. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
[TBL] [Abstract][Full Text] [Related]
9. Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.
Xin G; Chen Y; Topchyan P; Kasmani MY; Burns R; Volberding PJ; Wu X; Cohn A; Chen Y; Lin CW; Ho PC; Silverstein R; Dwinell MB; Cui W
Cancer Immunol Res; 2021 Apr; 9(4):454-469. PubMed ID: 33579728
[TBL] [Abstract][Full Text] [Related]
10. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
12. Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental Schistosoma japonicum infection.
Zhang Y; Wu Y; Liu H; Gong W; Hu Y; Shen Y; Cao J
Parasit Vectors; 2021 Sep; 14(1):497. PubMed ID: 34565440
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles.
Bayik D; Lauko AJ; Roversi GA; Serbinowski E; Acevedo-Moreno LA; Lanigan C; Orujov M; Lo A; Alban TJ; Kim A; Silver DJ; Nagy LE; Brown JM; Allende DS; Aucejo FN; Lathia JD
Sci Rep; 2020 Nov; 10(1):18848. PubMed ID: 33139767
[TBL] [Abstract][Full Text] [Related]
14. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
15. Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma.
Loeuillard EJ; Li B; Stumpf HE; Yang J; Willhite JR; Tomlinson JL; Rohakhtar FR; Simon VA; Graham RP; Smoot RL; Dong H; Ilyas SI
Cell Mol Gastroenterol Hepatol; 2024; 17(5):853-876. PubMed ID: 38219900
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
18. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Theivanthiran B; Evans KS; DeVito NC; Plebanek M; Sturdivant M; Wachsmuth LP; Salama AK; Kang Y; Hsu D; Balko JM; Johnson DB; Starr M; Nixon AB; Holtzhausen A; Hanks BA
J Clin Invest; 2020 May; 130(5):2570-2586. PubMed ID: 32017708
[TBL] [Abstract][Full Text] [Related]
19. M
Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
[TBL] [Abstract][Full Text] [Related]
20. Immune contexture of cholangiocarcinoma.
Paillet J; Kroemer G; Pol JG
Curr Opin Gastroenterol; 2020 Mar; 36(2):70-76. PubMed ID: 31895228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
